<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913662</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH_PIPAC_PTX</org_study_id>
    <nct_id>NCT04913662</nct_id>
  </id_info>
  <brief_title>Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel in Gastric Cancer Patients With Peritoneal Metastasis</brief_title>
  <official_title>Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel in Gastric Cancer Patients With Peritoneal Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospicare Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I trial investigating the safety of pressurized intraperitoneal aerosol&#xD;
      chemotherapy (PIPAC) using paclitaxel combined with intravenous FOLFOX therapy for gastric&#xD;
      cancer patients with peritoneal metastasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 26, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended dose</measure>
    <time_frame>Dose-limiting toxicity within 2 weeks after 1st intraoperative PIPAC (each cycle is 6 weeks)</time_frame>
    <description>Recommended dose of paclitaxel for a phase II trial</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Stomach Neoplasm</condition>
  <condition>Peritoneal Metastases</condition>
  <arm_group>
    <arm_group_label>PIPAC Paclitaxel with FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PIPAC (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pressurized Intraperitoneal Aerosol Chemotherapy</intervention_name>
    <description>Aerosolization of chemotherapic agent for intraperitoneal chemotherapy</description>
    <arm_group_label>PIPAC Paclitaxel with FOLFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically diagnosed as gastric adenocarcinoma&#xD;
&#xD;
          -  Imaging scans or diagnostic laparoscopic findings suggestive of peritoneal metastasis&#xD;
&#xD;
          -  HER-2 negative tumor&#xD;
&#xD;
          -  Laboratory tests adequate for chemotherapy (within 2 weeks of enrollment)&#xD;
&#xD;
          -  Absolute Neutrophil Count: ≧ 1,500/mm³&#xD;
&#xD;
          -  Hemoglobin level: ≧ 8.0g/dL&#xD;
&#xD;
          -  Platelet Count: ≧ 10×104/mm³&#xD;
&#xD;
          -  AST (GOT), ALT (GPT): ≦ 100U/L&#xD;
&#xD;
          -  Total Bilirubin: ≦ 2.0mg/dL&#xD;
&#xD;
          -  Creatinine Clearance (CCl): ≧ 50mL/min&#xD;
&#xD;
          -  ECOG 0 - 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with other major medical disease or malignant tumors other than gastric&#xD;
             cancer&#xD;
&#xD;
          -  Contraindication to 5-FU, Oxaliplatin, Leukovorin or Paclitaxel&#xD;
&#xD;
          -  Pregnant, breast-feeding women or with birth plan&#xD;
&#xD;
          -  History of gastrointestinal surgery&#xD;
&#xD;
          -  Patients refusing treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>So Hyun Kang</last_name>
    <phone>+82-10-7334-7124</phone>
    <email>shkang@snubh.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>So Hyun Kang</last_name>
      <phone>+82-10-7334-7124</phone>
      <email>shkang@snubh.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Hyung-Ho Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

